Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Remestemcel-L-Rknd · Ryoncil

Cell therapy (Stem-cell derived) · Immune activation · developed by Mesoblast

Approved FDA, Dec 2024
MESO Developer
1 Registered trials

What is Remestemcel-L-Rknd?

Remestemcel-L-rknd is an allogeneic cell therapy made of ex-vivo cultured adult human bone marrow-derived mesenchymal stromal cells. It is thought to act through immunomodulation, inhibiting T cell activation and pro-inflammatory cytokine secretion. It is studied in graft-versus-host disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ryoncil
Drug type
Cell therapy (Stem-cell derived)
Mechanism
Immune activation
Pathways
T cell activation inhibition, pro-inflammatory cytokine secretion
Therapy area
Immunology
Developer
Mesoblast (MESO)
FDA status
Approved as Ryoncil (December 18, 2024), BLA125706 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 11, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07568535 Phase 3 GVHD - Graft-Versus-Host Disease Not yet recruiting MESO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

GVHD - Graft-Versus-Host Disease

More from Mesoblast

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.

Follow MESO, the company behind Remestemcel-L-Rknd

See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MESO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.